Tonix Pharmaceuticals Holding Corp. (TNXP)
Data as of , from SEC Form 4 filings.
See up to 3 months of TNXP. The 7-day demo opens the 1M and 3M ranges and puts TNXP on your watchlist.
Start 7-day demoLatest TNXP insider trades
Seth Lederman - OfficerOpen-market purchase$28K- Richard H. Bagger - DirectorOpen-market purchase$13K
About Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
- BERKELEY HEIGHTS, NJ
- 142
- 2009
- XNAS
TNXP Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 3,000 | $40K |
TNXP insider transactions (Form 4)
3025 Form 4 filings on record, the earliest from May 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 2,000 | $13.79 | $28K | |
| Richard H. Bagger - Director | Open-market purchase | Common Stock, par value $0.001 | 1,000 | $12.60 | $13K | |
 Bradley Saenger - Officer | Other | Common Stock, $0.001 par value | 1,453 | $10.91 | $16K | |
 Carolyn E. Taylor - Director | Open-market purchase | Common Stock, $0.001 par value | 1,415 | $10.55 | $15K | |
| Richard Newcomb Stillwell - Director | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $11.65 footnote F1 | $58K | |
| ||||||
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $11.79 footnote F1 | $59K | |
| ||||||
| Richard Newcomb Stillwell - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| Adeoye Y. Olukotun - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
 Margaret Smith Bell - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| James Randolph Hunter Jr. - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| James Treco - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| David L. Grange - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| Richard H. Bagger - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| Carolyn E. Taylor - Director | Grant or award | Stock Option | 22,700 | $0.00 footnote F1 | - | |
| ||||||
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 5,000 | $12.62 footnote F1 | $63K | |
| ||||||
| Seth Lederman - Officer | Open-market purchase | Common Stock, $0.001 par value | 15,000 | $14.89 | $223K | |
| Jessica Edgar Morris - Officer | Grant or award | Stock Option | 39,012 | $0.00 footnote F2 | - | |
| Jessica Edgar Morris - Officer | Grant or award | Stock Option | 39,011 | $0.00 footnote F2 | - | |
| ||||||
| Bradley Saenger - Officer | Grant or award | Stock Option | 39,012 | $0.00 footnote F2 | - | |
| Bradley Saenger - Officer | Grant or award | Stock Option | 39,011 | $0.00 footnote F2 | - | |
| ||||||
 Gregory M. Sullivan - Officer | Grant or award | Stock Option | 39,012 | $0.00 footnote F2 | - | |
| Gregory M. Sullivan - Officer | Grant or award | Stock Option | 39,011 | $0.00 footnote F2 | - | |
| ||||||
 Siobhan Fogarty - Officer | Grant or award | Stock Option | 39,012 | $0.00 footnote F2 | - | |
| Siobhan Fogarty - Officer | Grant or award | Stock Option | 39,011 | $0.00 footnote F2 | - | |
| ||||||
| Seth Lederman - Officer | Grant or award | Stock Option | 134,504 | $0.00 footnote F2 | - | |
| Seth Lederman - Officer | Grant or award | Stock Option | 134,503 | $0.00 footnote F2 | - | |
| ||||||
| Carolyn E. Taylor - Director | Open-market purchase | Common Stock, par value $0.001 | 418 | $36.03 | $15K | |
| James Treco - Director | Open-market purchase | Common Stock, par value $0.001 | 250 | $36.00 | $9K | |
| David L. Grange - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
| Adeoye Y. Olukotun - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
Item 8.01
Item 8.01, 9.01
Item 8.01, 9.01
Item 5.02, 8.01
TNXP insider trading FAQ
What is the latest insider trade for TNXP?
Tonix Pharmaceuticals Holding Corp. (TNXP) had 2 insider filings in the last 90 days, with the most recent on 2026-08-31. The full record for TNXP runs to 25 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TNXP stock?
2 insider purchases of TNXP were filed in the last 90 days, totaling $40K.
How many insiders are selling TNXP stock?
No insider sales of TNXP were filed in the last 90 days.
Where can I see TNXP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TNXP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Seth Lederman view on EDGAR
- - Richard H. Bagger view on EDGAR
- - Bradley Saenger view on EDGAR
- - Carolyn E. Taylor view on EDGAR
- - Richard Newcomb Stillwell view on EDGAR
- - Seth Lederman view on EDGAR
- - Richard Newcomb Stillwell view on EDGAR
- - Adeoye Y. Olukotun view on EDGAR
- - Margaret Smith Bell view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where TNXP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TNXP with a 7-day demo
- TNXP on your watchlist
- Every TNXP Form 4 filing on record
- Up to 3 months of TNXP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
